Epeius Biotechnologies Corporation
| Article | Date | Source |
|---|
| Epeius Biotechnologies Corporation's REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation From the U.S. FDA | March 01, 2011 | BioSpace - Breaking News |
| Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy | November 08, 2010 | Biotech News - PR Newswire |
| Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents | July 06, 2010 | Biotech News - PR Newswire |
| Epeius Biotechnologies Corporation: Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies | May 25, 2010 | BioSpace - Breaking News |
| Epeius Biotechnologies Corporation: Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer | May 25, 2010 | BioSpace - Breaking News |
| Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy | May 04, 2010 | Biotech News - PR Newswire |
| Epeius Biotechnologies Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines | March 16, 2010 | Pharma News - PR Newswire |
| Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California | February 19, 2010 | Biotech News - PR Newswire |
View all the latest news
